Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in Chin...
"YuanSi ShengTai" completes Series B financing
AmoyDx obtained a medical device registration certificate
AmoyDx released its performance for the first three quarters, with a net profit attributable to the parent company of 263 million yuan, an increase of 15.50%
AmoyDx: Net profit in the third quarter was 73.4686 million yuan, a decrease of 11.92%
AmoyDx plans to increase its investment in upstream gene sequencing company SaiLu Medical by 50 million yuan
Innovative drug concept stocks are repeatedly active, CCHT has two consecutive limit-ups